These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 27138804)
1. MCL-1 is the key target of adjuvant chemotherapy to reverse the cisplatin-resistance in NSCLC. Ma J; Zhao Z; Wu K; Xu Z; Liu K Gene; 2016 Aug; 587(2):147-54. PubMed ID: 27138804 [TBL] [Abstract][Full Text] [Related]
2. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Wesarg E; Hoffarth S; Wiewrodt R; Kröll M; Biesterfeld S; Huber C; Schuler M Int J Cancer; 2007 Dec; 121(11):2387-94. PubMed ID: 17688235 [TBL] [Abstract][Full Text] [Related]
3. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells. Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126 [TBL] [Abstract][Full Text] [Related]
4. A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells. Li J; Viallet J; Haura EB Cancer Chemother Pharmacol; 2008 Mar; 61(3):525-34. PubMed ID: 17505826 [TBL] [Abstract][Full Text] [Related]
6. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Nguyen M; Marcellus RC; Roulston A; Watson M; Serfass L; Murthy Madiraju SR; Goulet D; Viallet J; Bélec L; Billot X; Acoca S; Purisima E; Wiegmans A; Cluse L; Johnstone RW; Beauparlant P; Shore GC Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19512-7. PubMed ID: 18040043 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. Mitchell C; Yacoub A; Hossein H; Martin AP; Bareford MD; Eulitt P; Yang C; Nephew KP; Dent P Cancer Biol Ther; 2010 Nov; 10(9):903-17. PubMed ID: 20855960 [TBL] [Abstract][Full Text] [Related]
8. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis. Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663 [TBL] [Abstract][Full Text] [Related]
9. Platinum resistant cancer cells conserve sensitivity to BH3 domains and obatoclax induced mitochondrial apoptosis. Crawford N; Chacko AD; Savage KI; McCoy F; Redmond K; Longley DB; Fennell DA Apoptosis; 2011 Mar; 16(3):311-20. PubMed ID: 21107700 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of MCL-1 by obatoclax sensitizes Sp2/0-Ag14 hybridoma cells to glutamine deprivation-induced apoptosis. Harnett CC; Abusneina A; Clément J; Gauthier ER Cell Biochem Funct; 2015 Jul; 33(5):334-40. PubMed ID: 26178811 [TBL] [Abstract][Full Text] [Related]
11. The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells. Peter B; Cerny-Reiterer S; Hadzijusufovic E; Schuch K; Stefanzl G; Eisenwort G; Gleixner KV; Hoermann G; Mayerhofer M; Kundi M; Baumgartner S; Sperr WR; Pickl WF; Willmann M; Valent P J Leukoc Biol; 2014 Jan; 95(1):95-104. PubMed ID: 24052572 [TBL] [Abstract][Full Text] [Related]
12. DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors. Li Y; Zhou D; Xu S; Rao M; Zhang Z; Wu L; Zhang C; Lin N Cancer Biol Med; 2020 May; 17(2):387-400. PubMed ID: 32587776 [No Abstract] [Full Text] [Related]
13. Clitocine induces apoptosis and enhances the lethality of ABT-737 in human colon cancer cells by disrupting the interaction of Mcl-1 and Bak. Sun JG; Xiang J; Zeng XL; Li X; Wu P; Fung KP; Liu FY Cancer Lett; 2014 Dec; 355(2):253-63. PubMed ID: 25304383 [TBL] [Abstract][Full Text] [Related]
14. Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells. Doi K; Gowda K; Liu Q; Lin JM; Sung SS; Dower C; Claxton D; Loughran TP; Amin S; Wang HG Cancer Biol Ther; 2014; 15(12):1688-99. PubMed ID: 25535900 [TBL] [Abstract][Full Text] [Related]
15. Cyclic GMP/protein kinase G type-Iα (PKG-Iα) signaling pathway promotes CREB phosphorylation and maintains higher c-IAP1, livin, survivin, and Mcl-1 expression and the inhibition of PKG-Iα kinase activity synergizes with cisplatin in non-small cell lung cancer cells. Wong JC; Bathina M; Fiscus RR J Cell Biochem; 2012 Nov; 113(11):3587-98. PubMed ID: 22740515 [TBL] [Abstract][Full Text] [Related]
16. Critical contribution of MCL-1 in EMT-associated chemo-resistance in A549 non-small cell lung cancer. Toge M; Yokoyama S; Kato S; Sakurai H; Senda K; Doki Y; Hayakawa Y; Yoshimura N; Saiki I Int J Oncol; 2015 Apr; 46(4):1844-8. PubMed ID: 25647738 [TBL] [Abstract][Full Text] [Related]
17. Defects in apoptotic signal transduction in cisplatin-resistant non-small cell lung cancer cells. Ikuta K; Takemura K; Kihara M; Naito S; Lee E; Shimizu E; Yamauchi A Oncol Rep; 2005 Jun; 13(6):1229-34. PubMed ID: 15870947 [TBL] [Abstract][Full Text] [Related]
18. Simultaneous targeting of ATM and Mcl-1 increases cisplatin sensitivity of cisplatin-resistant non-small cell lung cancer. Zhang F; Shen M; Yang L; Yang X; Tsai Y; Keng PC; Chen Y; Lee SO; Chen Y Cancer Biol Ther; 2017 Aug; 18(8):606-615. PubMed ID: 28686074 [TBL] [Abstract][Full Text] [Related]
19. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Lin X; Morgan-Lappe S; Huang X; Li L; Zakula DM; Vernetti LA; Fesik SW; Shen Y Oncogene; 2007 Jun; 26(27):3972-9. PubMed ID: 17173063 [TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibitors induce apoptosis in human lung cancer cells through a positive feedback mechanism and the subsequent Mcl-1 protein cleavage. Yuan BZ; Chapman J; Reynolds SH Oncogene; 2009 Oct; 28(43):3775-86. PubMed ID: 19684616 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]